ChemoMetec (CPSE:CHEMM) - Share price, News & Analysis

CHEMM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

CHEMM Stock Overview

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally.

Rewards

Earnings grew by 77.4% over the past year

Risk Analysis

High level of non-cash earnings

ChemoMetec Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChemoMetec
Historical stock prices
Current Share Price	kr.708.50
52 Week High	kr.1,149.00
52 Week Low	kr.595.50
Beta	1.36
1 Month Change	-21.50%
3 Month Change	-0.28%
1 Year Change	12.64%
3 Year Change	318.74%
5 Year Change	1,884.59%
Change since IPO	3,120.46%

Recent News & Updates

Mar 27

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Dec 12

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

	CHEMM	DK Life Sciences	DK Market
7D	1.2%	1.7%	1.5%
1Y	12.6%	-12.8%	3.4%

Return vs Industry: CHEMM exceeded the Danish Life Sciences industry which returned -11.3% over the past year.

Return vs Market: CHEMM exceeded the Danish Market which returned 3.3% over the past year.

Price Volatility

Is CHEMM's price volatile compared to industry and market?
CHEMM volatility
CHEMM Average Weekly Movement	7.7%
Life Sciences Industry Average Movement	7.8%
Market Average Movement	6.6%
10% most volatile stocks in DK Market	10.8%
10% least volatile stocks in DK Market	4.0%

Stable Share Price: CHEMM is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CHEMM's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	143	Steen Sondergaard	https://chemometec.com

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally. The company offers automated cell counters and image analyzers, such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-202, a consistent cell counter; and NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination. It also provides NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; and NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample.

ChemoMetec Fundamentals Summary

How do ChemoMetec's earnings and revenue compare to its market cap?
CHEMM fundamental statistics
Market Cap	kr.12.33b
Earnings (TTM)	kr.131.26m
Revenue (TTM)	kr.357.95m

94.0x

P/E Ratio

34.5x

P/S Ratio

Is CHEMM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CHEMM income statement (TTM)
Revenue	kr.357.95m
Cost of Revenue	kr.40.88m
Gross Profit	kr.317.07m
Other Expenses	kr.185.81m
Earnings	kr.131.26m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	7.54
Gross Margin	88.58%
Net Profit Margin	36.67%
Debt/Equity Ratio	0.3%

How did CHEMM perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

53%

Payout Ratio

Valuation

Is ChemoMetec undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

93.97x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: CHEMM (DKK708.5) is trading above our estimate of fair value (DKK107.31)

Significantly Below Fair Value: CHEMM is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: CHEMM is poor value based on its PE Ratio (94x) compared to the European Life Sciences industry average (45.3x).

PE vs Market: CHEMM is poor value based on its PE Ratio (94x) compared to the Danish market (13.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CHEMM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CHEMM is overvalued based on its PB Ratio (43.6x) compared to the XE Life Sciences industry average (3.4x).

Future Growth

How is ChemoMetec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ChemoMetec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has ChemoMetec performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

47.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CHEMM has a high level of non-cash earnings.

Growing Profit Margin: CHEMM's current net profit margins (36.7%) are higher than last year (30.4%).

Past Earnings Growth Analysis

Earnings Trend: CHEMM's earnings have grown significantly by 47.8% per year over the past 5 years.

Accelerating Growth: CHEMM's earnings growth over the past year (77.4%) exceeds its 5-year average (47.8% per year).

Earnings vs Industry: CHEMM earnings growth over the past year (77.4%) exceeded the Life Sciences industry 50.8%.

Return on Equity

High ROE: CHEMM's Return on Equity (46.4%) is considered outstanding.

Financial Health

How is ChemoMetec's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: CHEMM's short term assets (DKK238.6M) exceed its short term liabilities (DKK77.5M).

Long Term Liabilities: CHEMM's short term assets (DKK238.6M) exceed its long term liabilities (DKK11.1M).

Debt to Equity History and Analysis

Debt Level: CHEMM has more cash than its total debt.

Reducing Debt: CHEMM's debt to equity ratio has reduced from 35.3% to 0.3% over the past 5 years.

Debt Coverage: CHEMM's debt is well covered by operating cash flow (16739.8%).

Interest Coverage: CHEMM's interest payments on its debt are well covered by EBIT (259.7x coverage).

Balance Sheet

Dividend

What is ChemoMetec current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.56%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: CHEMM's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Danish market (1.39%).

High Dividend: CHEMM's dividend (0.56%) is low compared to the top 25% of dividend payers in the Danish market (5.91%).

Stability and Growth of Payments

Stable Dividend: CHEMM is not paying a notable dividend for the Danish market, therefore no need to check if payments are stable.

Growing Dividend: CHEMM is not paying a notable dividend for the Danish market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: CHEMM is not paying a notable dividend for the Danish market.

Cash Payout to Shareholders

Cash Flow Coverage: CHEMM is not paying a notable dividend for the Danish market.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure

CEO

Steen Sondergaard (62 yo)

2.33yrs

Tenure

Mr. Steen Sondergaard is the Chief Executive Officer at ChemoMetec A/S since January 2020 and served as its Chief Operating Officer & President.

Leadership Team

Experienced Management: CHEMM's management team is considered experienced (2.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30